Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1996 1
2004 1
2006 1
2007 1
2012 1
2013 1
2014 1
2015 1
2016 3
2017 3
2018 1
2019 2
2020 2
2021 6
2022 8
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management.
Ivanova M, Porta FM, Giugliano F, Frascarelli C, Sajjadi E, Venetis K, Cursano G, Mazzarol G, Guerini-Rocco E, Curigliano G, Criscitiello C, Fusco N. Ivanova M, et al. Genes (Basel). 2023 May 26;14(6):1160. doi: 10.3390/genes14061160. Genes (Basel). 2023. PMID: 37372340 Free PMC article. Review.
Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial.
Teng E, Manser PT, Pickthorn K, Brunstein F, Blendstrup M, Sanabria Bohorquez S, Wildsmith KR, Toth B, Dolton M, Ramakrishnan V, Bobbala A, Sikkes SAM, Ward M, Fuji RN, Kerchner GA; Tauriel Investigators. Teng E, et al. JAMA Neurol. 2022 Aug 1;79(8):758-767. doi: 10.1001/jamaneurol.2022.1375. JAMA Neurol. 2022. PMID: 35696185 Free PMC article. Clinical Trial.
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Ivanova M, Porta FM, D'Ercole M, Pescia C, Sajjadi E, Cursano G, De Camilli E, Pala O, Mazzarol G, Venetis K, Guerini-Rocco E, Curigliano G, Viale G, Fusco N. Ivanova M, et al. Virchows Arch. 2024 Jan;484(1):3-14. doi: 10.1007/s00428-023-03656-w. Epub 2023 Sep 28. Virchows Arch. 2024. PMID: 37770765 Free PMC article. Review.
Imaging Biomarkers in Alzheimer's Disease: A Practical Guide for Clinicians.
Sheikh-Bahaei N, Sajjadi SA, Manavaki R, Gillard JH. Sheikh-Bahaei N, et al. J Alzheimers Dis Rep. 2017 Jul 19;1(1):71-88. doi: 10.3233/ADR-170013. J Alzheimers Dis Rep. 2017. PMID: 30480230 Free PMC article. Review.
When the results of clinical examination and structural imaging, assessed by dementia expert, are still inconclusive, functional imaging can be used as a more advanced option. PET with ligands such as amyloid tracers and (18)F-fluorodeoxyglucose can improve the sensitivity …
When the results of clinical examination and structural imaging, assessed by dementia expert, are still inconclusive, functional imaging can …
Developmental expression and distinctive tyrosine phosphorylation of the Eph-related receptor tyrosine kinase Cek9.
Soans C, Holash JA, Pavlova Y, Pasquale EB. Soans C, et al. J Cell Biol. 1996 Nov;135(3):781-95. doi: 10.1083/jcb.135.3.781. J Cell Biol. 1996. PMID: 8909550 Free PMC article.
Cek9 is a receptor tyrosine kinase of the Eph subfamily for which only a partial cDNA sequence was known (Sajjadi, F.G., and E.B. Pasquale. 1993. Oncogene. 8:1807-1813). We have obtained the entire cDNA sequence and identified a variant form of Cek9 that lacks a sig …
Cek9 is a receptor tyrosine kinase of the Eph subfamily for which only a partial cDNA sequence was known (Sajjadi, F.G., and E …
37 results